Physician profile
Gwen L David
NPI 1225138308
$653.64
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $80.11 · 2021: $13.02 · 2022: $121 · 2023: $29.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $29.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $29.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $89.73 | 2019-2022 | |
| Lupin INC. | $79.54 | 2019-2020 | |
| Allergan, INC. | $69.06 | 2019 | |
| Vertical Pharmaceuticals, LLC | $54.54 | 2019 | |
| Celularity INC. | $49.47 | 2019-2020 | |
| Abbvie INC. | $48.95 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.24 | 2020-2022 | |
| Avion Pharmaceuticals | $39.18 | 2019-2022 | |
| Exeltis, USA INC. | $37.40 | 2019-2023 | Slynd |
| Duchesnay USA Incorporated | $28.57 | 2019 | |
| Amag Pharmaceuticals, INC. | $27.70 | 2019 | |
| Mayne Pharma Commercial LLC | $15.81 | 2023 | |
| Mylan Pharmaceuticals INC. | $15.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.87 | 2022 | |
| Evofem Biosciences, INC. | $14.15 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $12.39 | 2022 | |
| Pfizer INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gwen David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.